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SUMMARY. Esophageal and gastric cancer is associated with a poor prognosis since many patients develop
recurrent disease. Treatment requires specific expertise and a structured multidisciplinary approach. In the Neth-
erlands, this type of expertise is mainly found at the University Medical Centers (UMCs) and a few specialized
nonacademic centers. Aim of this study is to implement a national infrastructure for research to gain more insight in
the etiology and prognosis of esophageal and gastric cancer and to evaluate and improve the response on
(neoadjuvant) treatment. Clinical data are collected in a prospective database, which is linked to the patients’
biomaterial. The collection and storage of biomaterial is performed according to standard operating procedures in all
participating UMCs as established within the Parelsnoer Institute. The collected biomaterial consists of tumor
biopsies, blood samples, samples of malignant and healthy tissue of the resected specimen and biopsies of recurrence.
The collected material is stored in the local biobanks and is encoded to respect the privacy of the donors. After
approval of the study was obtained from the Institutional Review Board, the first patient was included in October
2014. The target aim is to include 300 patients annually. In conclusion, the eight UMCs of the Netherlands
collaborated to establish a nationwide database of clinical information and biomaterial of patients with esophageal
and gastric cancer. Due to the national coverage, a high number of patients are expected to be included. This will
provide opportunity for future studies to gain more insight in the etiology, treatment and prognosis of esophageal and
gastric cancer.
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INTRODUCTION
Esophageal and gastric cancer
The incidence of esophageal carcinoma is increasing
in developed countries, whereas the incidence of
gastric cancer has stabilized since its increase in the
1980s. The increase of esophageal cancer can mainly
be attributed to the increase in adenocarcinoma of
the esophagogastric junction among Caucasian
males.1–4 Esophageal cancer is now the sixth and
gastric cancer the second leading cause of cancer-
related mortality worldwide.3,4 The increased inci-
dence of esophageal carcinoma was also reported in
the Netherlands.5 In two decades (1989–2008), a
threefold increase was seen for esophageal cancer,
whereas the incidence of gastric cancer remained
stable.5 The specific etiological factors that contrib-
uted to the dramatic increase and the prognosis of the
disease are insufficiently elucidated.
Over the years, 5-year survival improved for
esophageal cancer due to the increased use of
neoadjuvant treatment and centralization of esopha-
geal cancer surgery. However, 5-year survival
remains poor.6–12 The recently conducted CROSS
trial showed that the overall 5-year survival after
chemoradiotherapy combined with surgery was 47%
in the Netherlands for patients with esophageal
cancer.13 For cardia and non-cardia gastric cancer,
long-term survival rates have not improved over the
past 20 years.14 The reported survival rates were 33%
and 50%, respectively, for cardia and non-cardia
gastric cancer treated with surgery.14 Many patients
with esophageal and gastric cancer develop meta-
static disease or locoregional recurrence, and it
remains difficult to predict which patients will
develop recurrence disease.
Treatment of esophageal and gastric cancer
requires a specific expertise and a structured multidis-
ciplinary approach. This type of expertise is mainly
found at the University Medical Centers (UMCs) and
a few specialized nonacademic centers in our country.
The UMCs have established a multidisciplinary col-
laboration to collect and store esophageal and gastric
cancer biomaterial and to link this information to
clinical data of the individual patients as part of the
Parelsnoer Institute (PSI).
History
The PSI was established in 2007 by the Dutch Fed-
eration of UMCs (NFU) with its main goal to
‘improve health by sharing science’. All eight UMCs
of the Netherlands collaborated to achieve a nation-
wide database of clinical data and biomaterial for
patients with selected medical conditions. Initially,
eight different patients cohorts, the so-called ‘pearls’,
were created by the PSI as seen in Table 1. However,
over the years more patient cohorts followed, and the
Esophageal and Gastric Cancer Pearl is now the 14th
patient cohort that has started collecting data. The
overall aim of the PSI was to realize a national infra-
structure within the UMCs to collect clinical data and
to set up a national biobank to collect biomaterial.
The clinical data are linked to the biomaterial, and
therefore it can be used to conduct more advanced
research. This may ultimately lead to better health
care in patients with the selected medical condition,
partly because treatment is more personalized (for
further information: http://www.parelsnoer.org).
Objective
The base of the Esophageal and Gastric Cancer Pearl
is to implement a national infrastructure for research
in patients with cancer of the esophagus and stomach.
The scientific goal is to initiate and stimulate scientific
research of high quality and of international impor-
tance. The main objective consists of three aims:
• To gain more knowledge in the etiology of esopha-
geal and gastric cancer;
• To evaluate and improve the response on
(neo)adjuvant and palliative treatment;
• To gain insight in the prognosis of esophageal and
gastric cancer.
STUDY DESIGN
Inclusion criteria and informed consent
The protocols for this multicenter study were
approved by the Institutional Review Board of the
Table 1 Parelsnoer Institute
Year Pearl (patient cohort)
2007 Cerebrovascular accident
Type II diabetes mellitus
Hereditary colorectal cancer






2010 CONCOR (congenital heart disease)
2011 Multiple endocrine neoplasms
Ischemic heart disease
Pancreatic cancer and chronic pancreatitis
2014 Esophageal and gastric tumors
Parkinson
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Biobank of the University Medical Center Utrecht.
Patients with (suspected) esophageal or gastric
tumors are eligible for inclusion into the esophageal
and gastric cancer pearl if examination takes place in
one of the following eight UMCs: Academic Medical
Center Amsterdam, Free University Medical Center
Amsterdam, University Medical Center Utrecht ,
Leiden University Medical Center, Erasmus Medical
Center Rotterdam, University Medical Center
Groningen, University Medical Center Nijmegen and
Maastricht University Medical Center (Atrium
Medical Center Heerlen, Orbis Medical Center
Sittard). Patients who undergo either an upper gas-
trointestinal endoscopy with the taking of biopsies to
confirm the diagnosis and/or who undergo an
esophagectomy or gastrectomy are included into the
Esophageal and Gastric Cancer Pearl. Informed
consent must be fully understood and signed prior to
the inclusion. The informed consent covers encoded
clinical data, biobanking, permission to approach the
municipality register for mortality follow-up and per-
mission to contact the general practitioner of the
patient to obtain important data. The participants
receive a copy of the signed informed consent.
Data collection
Clinical data entry is performed by the local coordi-
nating investigator. The prospective clinical database
is kept separately from the biobank with a secure
method to link encoded clinical information to tissue
samples. This database can exclusively be accessed by
authorized personnel. Biomaterial is also collected
and stored locally by the coordinating investigator.
Table 2 and Figure 1 shows the workflow and flow-
chart of the study. The collected data contains the
following items:
Demographics, patient’s characteristics and physical
examination
During the first visit at the outpatient clinic of the
participating hospital, information is gathered regard-
ing the following items: gender, date of birth, family
medical history, history of cancer-related illness or
surgery, comorbidities, lifestyle behavior and drug
use. Furthermore, a diagnosis-specific history is
obtained (i.e. dysphagia, reflux disease, weight loss,
etc.). Also, a screening physical examination is per-
formed, including assessment of length and weight.
Diagnostic workup
All patients receive an upper gastrointestinal endos-
copy. During endoscopy, biopsies of the suspected
malignancy are taken to confirm the diagnosis of
esophageal or gastric cancer and to retrieve biological
characteristics of the tumor. If possible, an additional
six biopsies are taken from the tumor to collect into
the biobank. Immediately after excision, three of
these samples are emersed in formalin in the endos-
copy room. The other three biopsies are put in
Eppendorf tubes with isopentane on dry ice to snap
freeze at the endoscopy unit. At the department of
pathology, the biopsies in formalin are embedded in
paraffin and the biopsies in the Eppendorf tubes are
directly put into the biobank freezers. Total time
from endoscopic excision to fixation and snap freez-
ing is kept to a minimum. Similarly, one paraffin
biopsy and one snap freeze biopsy of normal
mucosa are collected from the esophagus, the
esophagogastric junction and from the stomach, if
possible. The biopsies in paraffin are stored at room
temperature and the snap-frozen biopsies at −80°C in
the biobank.
Table 2 Work flow
Time management
ExecutiveT0 T1 T2 T3 T4 T5 T6–T10
Informed consent X – – – – – – PhD candidate / nurse practitioner
Demographics X – – – – – – PhD candidate / nurse practitioner
Medical history X – – – – – – PhD candidate / nurse practitioner
Comorbidities X – – – – – – PhD candidate / nurse practitioner
Life style behavior X – – – – – – PhD candidate / nurse practitioner
Diagnosis-specific anamnesis X – – – – – – Specialist
Screening physical examination X – – – – – – Specialist
Collecting biopsies of suspected tumor – X – – – – X Endoscopist
Collecting blood samples – X – – – X – Specialist
Data neoadjuvant treatment – – X – – – – PhD candidate / nurse practitioner
Collecting tissue samples – – – X – – – Specialist
Surgical data – – – X – – – PhD candidate / nurse practitioner
Data postoperative – – – – X – – PhD candidate / nurse practitioner
Data adjuvant treatment – – – – – X – PhD candidate / nurse practitioner
Follow-up – – – – – – X PhD candidate / nurse practitioner
T0, date of inclusion; T1, day of upper gastrointestinal endoscopy; T2, after confirmation of diagnosis and before surgery; T3, day of
surgery; T4, 30 days after surgery; T5, several weeks after surgery; T6, one year after surgery; T7, two years after surgery; T8, three years
after surgery; T9, four years after surgery; T10, five years after surgery.
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Blood samples
Samples of venous blood (serum, EDTA plasma and
EDTA blood for deoxyribonucleic acid [DNA]
extraction) are collected preoperatively and postop-
eratively. The blood samples are processed and stored
in certified biobank laboratories of the UMCs.
EDTA plasma and serum samples are obtained from
10 mL blood and are stored in 0.5 mL aliquots at
−80°C in the biobank. EDTA blood samples for
DNA extraction also consists of 10 mL blood, and
after a quality control is performed the DNA,
extracted within 4 weeks after venipuncture, is stored
at 4°C or lower in the biobank. Maximum time for
collecting, processing and storage of serum/plasma
samples is 4 hours.
Treatment
If patients are eligible, they receive either neoadjuvant
chemoradiation or perioperative chemotherapy
depending on the site of the tumor and according to
the Dutch upper gastrointestinal cancer guidelines.15
In case of a resectable tumor of the esophagus or
stomach, patients undergo either an esophagus-cardia
resection, partial or total gastrectomy or a total
esophagogastrectomy. During surgery, the resection
specimens are collected, and these are immediately
transported in an unfixed state in a sterile closed box to
the pathology department. At the department of
pathology, the resection specimens are reviewed and if
possible samples (0.5 cm3) of the tumor are removed to
collect into the biobank without compromising diag-
nostic histopathological staging. Three of these
samples are embedded in paraffin, and three are imme-
diately snap frozen in isopentane on dry ice in order to
maintain a good quality of DNA/RNA. The patholo-
gist also collects additional samples of normal tissue of
the esophagus, esophagogastric junction and stomach
for storage in the biobank. Of each site, one sample is
embedded in paraffin and one is snap frozen in
isopentane. Total time from excision to snap freezing
is estimated on 35 minutes. Information about the
neoadjuvant treatment (chemotherapy or chemo-
radiotherapy) and the surgical procedure (type of
resection, histopathological analysis) is entered in the
prospective database.
Postoperative data and follow-up
Clinical data are collected until 30 days after surgery
and consists of the following items: postoperative
complications, mortality, readmission, radicality of
resection, number of lymph nodes resected and stage
according to the TNM staging system.16 In case a
patient receives adjuvant treatment, information is
entered in the database. Follow-up is maintained for
a period of 5 years in the participating hospital.
During these 5 years, data about local recurrences,
distant metastasis, mortality and cause of death are
collected annually. If biopsies of a suspected recur-
rence or metastasis are taken for histopathological
confirmation, two additional biopsies are collected
for storage in the biobank. One sample is embedded
in paraffin, and one sample is snap frozen in
isopentane.
Biobanking
All UMCs have their own storage for biomaterial,
and together these storages form the national
biobank for the Esophageal and Gastric Cancer
Pearl. All materials are collected, identified,
analyzed and stored in the biobank according to
the standardized operating procedures established
within the PSI to ensure homogenous sample
Fig. 1 Flowchart of Esophageal and Gastric Cancer Pearl.
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collection. Each collected sample, as mentioned
before and specified in Table 3, receives a unique
sample code number, which is linked to the patient
identification number through a biobank manage-
ment information system software of the local
biobank. Before clinical data linked to unique
sample code numbers can be uploaded to the central
database, the local patient’s identification number is
encrypted via a trusted third party by special soft-
ware (Trusted Reversible Encryption Service®,
Houten, Utrecht, The Netherlands) to respect the
privacy of the donors and to ensure blinding of
researchers to analysis. Hence, the central database
contains encrypted clinical data linked to unique
sample code numbers.
Research
All participating researchers can submit their study
proposal to the scientific committee of the Esopha-
geal and Gastric Cancer Pearl to conduct research
with the clinical data and biomaterial gathered in the
database. The scientific committee, consisting of two
members of each UMC, judges the study proposal on
the following criteria: the study will lead to novel
insights regarding esophageal and gastric cancer, the
study complies with requirements of an effective
research methodology, the study will be performed
by qualified investigators, the study is feasible and
suitable. After acceptance of the research proposal
by the scientific committee, the study can be
conducted.
Funding
The founding of the PSI was co-financed by the
Dutch Government, the NFU and the eight UMCs in
the Netherlands. The continuation of the PSI is
financed by the UMCs.
DISCUSSION
The biobank for the Esophageal and Gastric Cancer
Pearl is designed to prospectively collect clinical data
and biomaterial for research to gain more insight in
its etiology, treatment and prognosis. In an era of
increased interest in personalized medicine, the
linkage of molecular data and genetic profiling to
demographic, pathologic and clinical records will
greatly enhance future studies of cancer etiology and
risk factors. Moreover, the information about recur-
rences and survival status related to treatment thera-
pies and genetic profiling will provide much
information on progression and outcome of the
disease.
Realizing their significance, biobanks have been
established at national levels in many countries with
strict regulations. For example, the General Practi-
tioners Research Database in the UK was established
to recruit more than half a million volunteers to
collect blood and urine samples from 2006 to 2010.17
These samples were linked to information obtained
from questionnaires and physical information and
have been valuable in many research topics concern-
ing diabetes, major depression, osteoporosis and
Table 3 Collecting biomaterial
Material Amount Frequency Notification Storage Storage units
Blood samples












−80°C Preferably 5 × 0.5 mL
3 EDTA blood sample
for DNA or pellet
from tube 1
1 × 10 mL 1 preoperative Mandatory 4°C or ≤20°C ≥2 aliquots DNA stock
solution
Tissue samples




12† 1 during endoscopy Recommended Three paraffin and three
frozen samples from
normal tissue one each
Resection specimen 6 × 0.5 cm3 1 at surgery Mandatory Preferably three paraffin




6 × 0.5 cm3 1 at surgery Mandatory One paraffin and one
frozen sample per site
Biopsies
recurrence/metastasis
2 Day of diagnostics Recommended One paraffin and one
frozen sample
†Only if possible. DNA, deoxyribonucleic acid; EDTA, Ethylenediaminetetraacetic acid; EGJ, esophagogastric junction.
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many more.18–20 Furthermore, the Esophageal and
Gastric Center within the Academic Medical Center
of Dublin has developed a repository of fresh frozen
tissue, DNA, RNA and serum on patients with pre-
malignant and malignant esophageal disease in
2004.21 They have collected samples of 420 patients in
6 years and used these samples for studies that
included leptin and adiponectin receptor expression
in esophageal cancer,22 prognostic significance
of neuroepithelial transforming gene-1 in adeno-
carcinoma of the esophagogastric junction23 and
more. Lastly, the Oesophageal Cancer Clinical and
Molecular Stratification (OCCAMS) study group in
the UK has started a similar program for tissue and
data collection of patients with esophageal cancer
across multiple specialist centers. They aimed to
determine prognostic biomarkers and therapeutic
targets for esophageal adenocarcinoma including
whole genome sequencing.24,25 Also in the Nether-
lands, a national biobank has been established (PSI),
which originally started collecting data of eight
patient cohorts. It has now grown to 14 patient
cohorts of selected medical conditions, and its growth
is still expanding.
The Esophageal and Gastric Cancer Pearl is estab-
lished to implement a national infrastructure for
research in patients with cancer of the esophagus and
stomach, which will allow us to gain more insight in
the etiology and prognosis of esophageal and gastric
cancer and to evaluate and improve the response on
(neoadjuvant) treatment. The specific strength of the
Esophageal and Gastric Cancer Pearl is the ability to
compare and follow patients with different stages of
esophageal and gastric cancer at a molecular and
genetic level, which brings us a step closer to the
identification of biomarkers for the diagnosis and
progression of the disease. Furthermore, it allows
us to study the sensitivity and resistance to neoad-
juvant treatment. Prediction of pathologically
complete response and nonresponse to neoadjuvant
chemoradiotherapy by analysis of tissues and genetic
profiling is of great clinical importance and could
allow to decide what is the optimal treatment in each
individual. Another clear strength of the Esophageal
and Gastric Cancer Pearl is that healthy tissue is
collected from the esophagus, esophagogastric junc-
tion and stomach. This will allow to directly compare
acquired disease-related alterations within the genetic
background of the patients.
The most important factor for achieving our goals
is the implementation of a solid national research
infrastructure that contains a standardized data col-
lection and a solid long-term storage strategy. Due to
the longitudinal character of research with biobank
materials, it is necessary to ensure data harmoniza-
tion over a long period of time. This will contribute
to high-quality investigations for generations of
researchers. We are realizing this by the use of the
standard operating procedures to store biomaterial,
which was released into the public domain by the
Canadian Tumor Repository Network26 and by a
secured method to link clinical information to tissue
samples. Some considerations are raised concerning
ethics regarding the collection of data. Before inclu-
sion of the patients in this study, written informed
consent is required. Furthermore, data entry is
uploaded in an encoded manner, in order to ensure
privacy of the patients as well as remaining the pos-
sibility to trace biological samples and data back to
the original participant for linkage to follow-up.
However, only exclusive personnel are authorized to
access the secured code.
PERSPECTIVES
Thanks to the collaboration between the UMCs, the
Esophageal and Gastric Cancer Pearl has a national
coverage. Most of the patients with esophageal and
gastric cancer are treated in UMCs in our country
and therefore a high percentage of these patients will
be included into the Esophageal and Gastric Cancer
Pearl. The first patient was included in October 2014,
after which data collection has started. The target aim
is to include 300 esophageal and gastric cancer
patients annually. With this great number of patients,
promising results can be expected in the near future.
CONCLUSION
In conclusion, the eight UMCs of the Netherlands
collaborate within the Parelsnoer Institute to estab-
lish a nationwide database of clinical information and
biomaterial in patients with esophageal and gastric
cancer. This collection of data will aid in gaining
more insight in the etiology and prognosis of esopha-
geal and gastric cancer and to evaluate and improve
the response on (neoadjuvant) treatment.
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